Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
| ▸ | RAD51 | Q06609 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19726904 | 0.93 | ENPP2 (0.41) | ENPP2RAD51RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL17830396 | 0.92 | ENPP2 (0.48) | ENPP2RAD51RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL19713069 | 0.89 | ENPP2 (0.53) | ENPP2RAD51RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL17830394 | 0.89 | ENPP2 (0.53) | ENPP2RAD51RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL19713046 | 0.88 | RAD51 (0.39) | ENPP2RAD51RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL17830247 | 0.87 | ENPP2 (0.51) | ENPP2RAD51RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL19726902 | 0.86 | KDM4E (0.37) | ENPP2RAD51RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL19726903 | 0.85 | ENPP2 (0.42) | ENPP2RAD51RAB9ASMN1; SMN2KDM4E | |
| SCHEMBL17830249 | 0.84 | ENPP2 (0.53) | ENPP2RAD51RAB9AKDM4EAPEX1 | |
| SCHEMBL19713037 | 0.84 | ENPP2 (0.53) | ENPP2RAD51RAB9AKDM4EAPEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10927075-B2 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease | THE JACKSON LABORATORY (US) | 2021-02-23 | — | — | US | disclosed |
| US-20170362172-A1 | COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF CANCER, AUTOIMMUNE DISEASE, AND NEURODEGENERATIVE DISEASE | THE JACKSON LABORATORY (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2016094897-A1 | COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF CANCER, AUTOIMMUNE DISEASE, AND NEURODEGENERATIVE DISEASE | THE JACKSON LABORATORY (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362172-A1 | COMPOSITIONS AND METHODS RELATING TO THE TREATMENT OF CANCER, AUTOIMMUNE DISEASE, AND NEURODEGENERATIVE DISEASE | OGG1, MGMT, TDP1 | ENPP2 225/4885RAD51 35/4885RAB9A 2826/4885 |
| US-10927075-B2 | Compositions and methods relating to the treatment of cancer, autoimmune disease, and neurodegenerative disease | OGG1, MGMT, TDP1 | ENPP2 225/4885RAD51 35/4885RAB9A 2826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.